Mediwound (NASDAQ:MDWD) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Mediwound (NASDAQ:MDWD) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Separately, Zacks Investment Research upgraded Mediwound from a sell rating to a hold rating in a research report on Friday, July 12th.

Mediwound stock traded down $0.01 during trading hours on Thursday, hitting $2.58. The stock had a trading volume of 112,271 shares, compared to its average volume of 67,068. The company has a current ratio of 3.99, a quick ratio of 3.79 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $76.64 million, a PE ratio of -5.27 and a beta of 0.49. Mediwound has a one year low of $2.55 and a one year high of $6.75. The business has a 50 day moving average of $3.36.

Mediwound (NASDAQ:MDWD) last posted its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.60 million. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. As a group, analysts anticipate that Mediwound will post -0.59 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in Mediwound in the first quarter valued at about $93,000. Delek Group Ltd. acquired a new stake in shares of Mediwound in the first quarter valued at about $141,000. Oppenheimer & Co. Inc. increased its stake in shares of Mediwound by 6.5% in the first quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 2,000 shares during the period. Deutsche Bank AG increased its stake in shares of Mediwound by 73.5% in the fourth quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 16,840 shares during the period. Finally, Menta Capital LLC increased its stake in shares of Mediwound by 200.2% in the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29,686 shares during the period. Hedge funds and other institutional investors own 30.78% of the company’s stock.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Story: How are the companies in the S&P 500 selected?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.